Visit https://www.peervoice.com/BFC860 to view the entire programme with slides. After completing “Incretin Effect 101: Why We Need to Look Beyond GLP-1 in T2DM”, participants will be able to: Discuss emerging clinical evidence for incretin therapies for type 2 diabetes (T2DM) and how this data may impact future management strategies; Describe the function of incretin hormones and their role in the pathogenesis of T2DM; Recognise the benefits of incretin therapies beyond glycaemic control in patients with T2DM.